Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit

Circulation: Arrhythmia and Electrophysiology

Volumn 5, Issue 4, 2012, Pages 706-713

  Parkash, Ratika ^a   Sapp, John L ^a   Basta, Magdy ^a   Doucette, Steve ^b   Thompson, Kara ^a   Gardner, Martin ^a   Gray, Chris ^a   Brownell, Brenda ^a   Kidwai, Hena ^a   Cox, Jafna ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Defibrillation; Registries; Sudden cardiac arrest; Sudden death; Survival

Indexed keywords

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEFIBRILLATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SUDDEN DEATH; SURVIVAL;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NOVA SCOTIA; PATIENT SELECTION; PRIMARY PREVENTION; PROPENSITY SCORE; REFERRAL AND CONSULTATION; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867160141     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.112.970798     Document Type: Article

References (42)

1. Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, Kerber RE, Naccarelli GV, Schoenfeld MH, Silka MJ, Winters SL, Gibbons RJ, Antman EM, Alpert JS, Gregoratos G, Hiratzka LF, Faxon DP, Jacobs AK, Fuster V, Smith SC Jr; American College of Cardiology/American Heart Association Task Force on Practice Guidelines/North American Society for Pacing and Electrophysiology Committee to Update the 1998 Pacemaker Guidelines. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002;106:2145-2161. (Pubitemid 35192824)
2. Tang AS, Ross H, Simpson CS, Mitchell LB, Dorian P, Goeree R, Hoffmaster B, Arnold M, Talajic M; Canadian Heart Rhythm Society; Canadian Cardiovascular Society. Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol. 2005;21 Suppl A:11A-18A. (Pubitemid 46489507)
3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883. (Pubitemid 34984635)
4. Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer GS, Prystowsky EN, O'Toole MF, Tang A, Fisher JD, Coromilas J, Talajic M, Hafley G; Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med. 2000;342:1937-1945. (Pubitemid 30419088)
5. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237. (Pubitemid 40110811)
6. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, Levine JH, Saksena S, Waldo AL, Wilber D, Brown MW, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940. (Pubitemid 26428217)
7. Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, Block M, Gietzen F, Berger J, Kuck KH. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453-1458. (Pubitemid 34263277)
8. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, Bitar C, Morady F; AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-1712. (Pubitemid 36584239)
9. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
10. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH; Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158. (Pubitemid 38637995)
11. Julian DG. What is right and what is wrong about evidence-based medicine? J Cardiovasc Electrophysiol. 2003;14(9 Suppl):S2-S5. (Pubitemid 37115129)
12. Strobel JS, Epstein AE. Large clinical trials in the management of ventricular arrhythmias: applying group results to individual cases. Cardiol Clin. 2000;18:337-56, viii.
13. Every NR, Hlatky MA, McDonald KM, Weaver WD, Hallstrom AP. Estimating the proportion of post-myocardial infarction patients who may benefit from prophylactic implantable defibrillator placement from analysis of the CAST registry. Cardiac Arrhythmia Suppression Trial. Am J Cardiol. 1998;82:683-5, A8. (Pubitemid 28397676)
14. Dhruva SS, Redberg RF. Variations between clinical trial participants and Medicare beneficiaries in evidence used for Medicare national coverage decisions. Arch Intern Med. 2008;168:136-140. (Pubitemid 351185879)
15. McCann DJ. 2009 Demographic update: Nova Scotia perspective. Release No. 2, Population Estimates: by Economic Region. January 2010.
16. Cox JL. Optimizing disease management at a health care system level: the rationale and methods of the improving cardiovascular outcomes in Nova Scotia (ICONS) study. Can J Cardiol. 1999;15:787-796. (Pubitemid 29368894)
17. Parsons LS. SUGI 26: Reducing bias in a propensity score matched-pair sample using greedy matching techniques. SAS Institute, Cary, NC, 2001.
18. Gillis AM, Philippon F, Cassidy MR, Singh N, Dorian P, Love BA, Kerr CR; Canadian Working Group on Cardiac Pacing. Guidelines for implantable cardioverter defibrillator follow-up in Canada: a consensus statement of the Canadian Working Group on Cardiac Pacing. Can J Cardiol. 2003;19:21-37. (Pubitemid 36304697)
19. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27:2037-2049. (Pubitemid 351772300)
20. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156. (Pubitemid 43987579)
21. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-259.
22. Parsons LS. SUGI 29: Performing a 1:N case-control match on propensity score. The SAS Institure 2004. http://www2.sas.com/proceedings/sugi29/165-29. pdf.
23. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation. 2008;117:1918-1926. (Pubitemid 351543467)
24. Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W; Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II. Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II. Circulation. 2010;122:1265-1271.
25. Nanthakumar K, Epstein AE, Kay GN, Plumb VJ, Lee DS. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. J Am Coll Cardiol. 2004;44:2166-2172. (Pubitemid 39576036)
26. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML, Wilber DJ, Klein HU; MADIT-II Investigators. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:1811-1817.
27. Parkash R, Tang A, Wells G, Blackburn J, Stiell I, Simpson C, Dorian P, Yee R, Cameron D, Connolly S, Birnie D, Nichol G. Use of implantable cardioverter defibrillators after out-of-hospital cardiac arrest: a prospective follow-up study. CMAJ. 2004;171:1053-1056. (Pubitemid 39468713)
28. Birnie DH, Sambell C, Johansen H, Williams K, Lemery R, Green MS, Gollob MH, Lee DS, Tang AS. Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest. CMAJ. 2007;177:41-46. (Pubitemid 47041130)
29. Pertzov B, Novack V, Zahger D, Katz A, Amit G. Insufficient compliance with current implantable cardioverter defibrillator (ICD) therapy guidelines in post myocardial infarction patients is associated with increased mortality. Int J Cardiol. November 16, 2011. doi:10.1016/j.ijcard.2011.10.132. Available at: http://www.internationaljournalofcardiology.com/article/S0167-5273%2811%2902023- 7/fulltext. Accessed December 10, 2011.
30. Shah B, Hernandez AF, Liang L, Al-Khatib SM, Yancy CW, Fonarow GC, Peterson ED; Get With The Guidelines Steering Committee. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. J Am Coll Cardiol. 2009;53:416-422.
31. Boriani G, Rapezzi C, Diemberger I, Gonzini L, Gorini M, Lucci D, Sinagra G, Cooke RM, Di Pasquale G, Tavazzi L, Maggioni AP. Trialgenerated profiles for implantation of electrical devices in outpatients with heart failure: real-world prevalence and 1-year outcome. J Eval Clin Pract. 2010;16:82-91.
32. Wolpert C, Lubinski A, Bissinger A, Merkely B, Priori S, Brugada J. Barriers to implementation of evidence-based electrical therapies and the need for outcome research: role of European registries. Europace. 2011;13 Suppl 2:ii18-ii20.
33. Gravelin LM, Yuhas J, Remetz M, Radford M, Foley J, Lampert R. Use of a screening tool improves appropriate referral to an electrophysiologist for implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. Circ Cardiovasc Qual Outcomes. 2011;4:152-156.
34. Hernandez AF, Fonarow GC, Liang L, Al-Khatib SM, Curtis LH, LaBresh KA, Yancy CW, Albert NM, Peterson ED. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA. 2007;298:1525-1532. (Pubitemid 47529386)
35. Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O'Flaherty M, Krahn M, Capewell S. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA. 2010;303:1841-1847.
36. Schellenberg G, Turcotte M. A portrait of seniors in Canada. Statistics Canada. 2006.
37. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385-2395.
38. Wells G, Parkash R, Healey JS, Talajic M, Arnold JM, Sullivan S, Peterson J, Yetisir E, Theoret-Patrick P, Luce M, Tang AS. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ. 2011;183:421-429.
39. Sweeney MO, Wathen MS, Volosin K, Abdalla I, DeGroot PJ, Otterness MF, Stark AJ. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 2005;111:2898-2905. (Pubitemid 40814182)
40. Undavia M, Goldstein NE, Cohen P, Sinthawanarong K, Singson M, Bhutani D, Munson T, Gomes JA, Fischer A, Mehta D. Impact of implantable cardioverter-defibrillator recalls on patients' anxiety, depression, and quality of life. Pacing Clin Electrophysiol. 2008;31:1411-1418.
41. Gould PA, Gula LJ, Champagne J, Healey JS, Cameron D, Simpson C, Thibault B, Pinter A, Tung S, Sterns L, Birnie D, Exner D, Parkash R, Skanes AC, Yee R, Klein GJ, Krahn AD. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm. 2008;5:1675-1681.
42. Parkash R, Crystal E, Bashir J, Simpson C, Birnie D, Sterns L, Exner D, Thibault B, Connors S, Healey JS, Champagne J, Cameron D, Mangat I, Verma A, Wolfe K, Essebag V, Kus T, Ayala-Paredes F, Davies T, Sanatani S, Gow R, Coutu B, Sivakumaran S, Stephenson E, Krahn A. Complications associated with revision of Sprint Fidelis leads: report from the Canadian Heart Rhythm Society Device Advisory Committee. Circulation. 2010;121:2384-2387.